Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01446198 · ClinicalTrials.gov registry record
Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHER™ System
A clinical trial, sponsored by Gen-Probe, Incorporated.
- Completed
- Registry status
- 11,816
- Enrollment target
NCT01446198: Completed study, sponsored by Gen-Probe, Incorporated.
NCT01446198 is a clinical trial that has completed, run by Gen-Probe, Incorporated. The registered enrollment target is 11,816 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01446198 has completed, sponsored by Gen-Probe, Incorporated.
- COMPLETED
- Registry status
- 11,816 participants
- Enrollment target
Study Summary
The objective is to establish that APTIMA HPV Assay performance on the PANTHER System is comparable to performance on the TIGRIS System.
Primary Outcome
Percent Positive Agreement: The number of samples with a positive HPV Assay result on TIGRIS and PANTHER divided by the number of samples with a positive HPV Assay result on TIGRIS, multiplied by 100 Percent Negative Agreement: The number of samples with a negative HPV Assay result on TIGRIS and PANTHER divided by the number of samples with a negative HPV Assay result on TIGRIS, multiplied by 100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,816 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-05 |
What the finished NCT01446198 record still lists
NCT01446198 is an observational study that tracks outcomes without assigning an intervention. Its 11,816 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01446198 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01446198 about?
NCT01446198 is a clinical study titled "Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHER™ System". The objective is to establish that APTIMA HPV Assay performance on the PANTHER System is comparable to performance on the TIGRIS System.
What is the current status of trial NCT01446198?
This trial is currently completed. The enrollment target is 11,816 participants. The study started on 2012-03. Estimated completion is 2012-05.
Who is sponsoring clinical trial NCT01446198?
This trial is sponsored by Gen-Probe, Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07064473 · 11,800 participants · Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- NCT01772771 · 12,000 participants
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- NCT04937868 · 12,000 participants
Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients
- NCT06059963 · 12,000 participants
A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia